LeukoScan (sulesomab)
- Region
- 🇪🇺 EU
- Active substance
- sulesomab
- Company
- Immunomedics GmbH
- Status
- Withdrawn
- Therapeutic area
- Osteomyelitis; Radionuclide Imaging
- EU approval
- Fri 14 Feb 1997
- Application
- EMEA/H/C/000111
- ATC
- VO4D
- Official record
- www.ema.europa.eu
Indication
This medicinal product is for diagnostic use only. LeukoScan is indicated for diagnostic imaging for determining the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers. LeukoScan has not been employed to diagnose osteomyelitis in patients with sickle cell anaemia.
Regulatory milestones
No milestones recorded in the last year.
Follow LeukoScan
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.